TY - JOUR
T1 - The STRIDE weight loss and lifestyle intervention for individuals taking antipsychotic medications
T2 - A randomized trial
AU - Green, Carla A.
AU - Yarborough, Bobbi Jo H.
AU - Leo, Michael C.
AU - Yarborough, Micah T.
AU - Stumbo, Scott P.
AU - Janoff, Shannon L.
AU - Perrin, Nancy A.
AU - Nichols, Greg A.
AU - Stevens, Victor J.
PY - 2015/1/1
Y1 - 2015/1/1
N2 - Objectives: The STRIDE study assessed whether a lifestyle intervention, tailored for individuals with serious mental illnesses, reduced weight and diabetes risk. The authors hypothesized that the STRIDE interventionwould be more effective than usual care in reducing weight and improving glucose metabolism. Method: The study design was a multisite, parallel two-arm randomized controlled trial in community settings and an integrated health plan. Participantswho met inclusion criteria were ≥;18 years old, were taking antipsychotic agents for ≥;30 days, andhad a body mass index ≥;27. Exclusionswere significant cognitive impairment, pregnancy/breastfeeding, recent psychiatric hospitalization, bariatric surgery, cancer, heart attack, or stroke. The intervention emphasizedmoderate caloric reduction, the DASH (Dietary Approaches to Stop Hypertension) diet, and physical activity. Blindedstaffcollecteddataatbaseline,6months,and12months. Results: Participants (men, N=56; women, N=144; mean age=47.2 years [SD=10.6]) were randomly assigned to usual care (N=96) or a 6-month weekly group intervention plus six monthly maintenance sessions (N=104). A total of 181 participants (90.5%) completed 6-month assessments, and 170 (85%) completed 12-month assessments,without differential attrition. Participants attended 14.5 of 24 sessions over 6 months. Intent-to-treat analyses revealed that intervention participants lost 4.4 kg more than control participants from baseline to 6 months (95% CI=-6.96 kg to -1.78 kg) and 2.6 kg more than control participants from baseline to 12 months (95% CI=-5.14 kg to -0.07 kg). At 12 months, fasting glucose levels in the control group had increased from 106.0 mg/dL to 109.5 mg/dL and decreased in the intervention group from 106.3 mg/dL to 100.4 mg/dL. No serious adverse events were study-related; medical hospitalizations were reduced in the intervention group (6.7%) compared with the control group (18.8%). Conclusions: Individuals taking antipsychotic medications can loseweight and improve fasting glucose levels. Increasing reach of the intervention is an important future step.
AB - Objectives: The STRIDE study assessed whether a lifestyle intervention, tailored for individuals with serious mental illnesses, reduced weight and diabetes risk. The authors hypothesized that the STRIDE interventionwould be more effective than usual care in reducing weight and improving glucose metabolism. Method: The study design was a multisite, parallel two-arm randomized controlled trial in community settings and an integrated health plan. Participantswho met inclusion criteria were ≥;18 years old, were taking antipsychotic agents for ≥;30 days, andhad a body mass index ≥;27. Exclusionswere significant cognitive impairment, pregnancy/breastfeeding, recent psychiatric hospitalization, bariatric surgery, cancer, heart attack, or stroke. The intervention emphasizedmoderate caloric reduction, the DASH (Dietary Approaches to Stop Hypertension) diet, and physical activity. Blindedstaffcollecteddataatbaseline,6months,and12months. Results: Participants (men, N=56; women, N=144; mean age=47.2 years [SD=10.6]) were randomly assigned to usual care (N=96) or a 6-month weekly group intervention plus six monthly maintenance sessions (N=104). A total of 181 participants (90.5%) completed 6-month assessments, and 170 (85%) completed 12-month assessments,without differential attrition. Participants attended 14.5 of 24 sessions over 6 months. Intent-to-treat analyses revealed that intervention participants lost 4.4 kg more than control participants from baseline to 6 months (95% CI=-6.96 kg to -1.78 kg) and 2.6 kg more than control participants from baseline to 12 months (95% CI=-5.14 kg to -0.07 kg). At 12 months, fasting glucose levels in the control group had increased from 106.0 mg/dL to 109.5 mg/dL and decreased in the intervention group from 106.3 mg/dL to 100.4 mg/dL. No serious adverse events were study-related; medical hospitalizations were reduced in the intervention group (6.7%) compared with the control group (18.8%). Conclusions: Individuals taking antipsychotic medications can loseweight and improve fasting glucose levels. Increasing reach of the intervention is an important future step.
UR - http://www.scopus.com/inward/record.url?scp=84920170620&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84920170620&partnerID=8YFLogxK
U2 - 10.1176/appi.ajp.2014.14020173
DO - 10.1176/appi.ajp.2014.14020173
M3 - Article
C2 - 25219423
AN - SCOPUS:84920170620
SN - 0002-953X
VL - 172
SP - 71
EP - 81
JO - American Journal of Psychiatry
JF - American Journal of Psychiatry
IS - 1
ER -